The Challenges of Acute Interstitial Nephritis: Time to Standardize
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Acute interstitial nephritis (AIN) is a well-known cause of acute kidney disease (AKD) and CKD and is associated with progression to ESKD (1⇓⇓⇓⇓–6). Accordingly, it represents an important problem for clinicians caring for these patients. AIN is primarily an immune-mediated kidney injury triggered by use of certain medications, in particular antibiotics, PPIs, NSAIDs, and immune checkpoint inhibitors (ICPIs), or by autoimmune diseases, such as Sjogren syndrome, sarcoidosis, IgG4-related tubulointerstitial disease, and TINU. In developed countries, medications are the most common cause of AIN (>70%), whereas the number approximates 50% in developing countries. Infectious agents are a less common cause of AIN, except in developing countries. The overall incidence of AIN in kidney biopsy registries is 2%–5%, whereas AIN is observed in approximately 15%–20% of patients with AKI or AKD who undergo kidney biopsy (1⇓–3). The actual number is likely higher as many patients with AKI/AKD do not undergo biopsy and are presumed to have acute tubular injury (ATI). Importantly, diagnosing AIN clinically is often quite challenging, making kidney biopsy a frequent requirement to definitively confirm the diagnosis and guide therapy (Figure 1). Furthermore, delayed or missed AIN diagnosis leads to ongoing inflammation with resulting interstitial fibrosis, tubular atrophy, and permanent kidney damage, which may be the explanation for CKD occurring in 40%–60% of patients after an episode of AIN (4,5). Approximately 2% of CKD is considered to be due to AIN, which is equivalent to 10 million prevalent worldwide cases. Furthermore, AIN is the primary cause of ESKD in 3%–4% of incident patients (6). It is one of the few potentially treatable causes of AKI if identified and treated early. In view of these data, three key challenges that limit the diagnosis and management of patients suspected of having …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Histopathologically, the presence of moderate to severe IFTA was significantly associated with worse kidney outcomes, consistent with previous studies.”
From Clinicopathological Characteristics and Kidney Outcomes in Biopsy-Confirmed Acute Interstitial Nephritis (2024) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Bragg-Gresham, J., Chen, X., Gipson, D., Gu, H., Hirth, R. A., Hutton, D., Jin, Y., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.09.003 · Cited by 992
Biopsy-proven acute interstitial nephritis, 1993-2011: a case series
Muriithi, A. K., Leung, N., Valeri, A. M., Cornell, L. D., Sethi, S., Fidler, M. E., & Nasr, S. H. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.027 · Cited by 337
Haas, M., Spargo, B. H., Wit, E.-J. C., & Meehan, S. M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70196-x · Cited by 269
Nochaiwong, S., Ruengorn, C., Awiphan, R., Koyratkoson, K., Chaisai, C., Noppakun, K., Chongruksut, W., & Thavorn, K. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw470 · Cited by 185
Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases
SIMPSON, I. J., MARSHALL, M. R., PILMORE, H., MANLEY, P., WILLIAMS, L., THEIN, H., & VOSS, D. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00651.x · Cited by 157
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154 · cited 6×
“This reclassification was lower when AIN was listed as the first diagnosis (18%) than when it was listed as second or later diagnosis (41%) (20).”
BackgroundSelf-citationInvolvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis
Spanou, Z., Keller, M., Britschgi, M., Yawalkar, N., Fehr, T., Neuweiler, J., Gugger, M., Mohaupt, M., & Pichler, W. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050418 · Cited by 151
Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis
Muriithi, A. K., Nasr, S. H., & Leung, N. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01330213 · Cited by 144
Drug-Induced Acute Interstitial Nephritis
Moledina, D. G., & Perazella, M. A. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07630717 · Cited by 133
Self-citation
Cited by
Longitudinal biomarkers and kidney disease progression after acute kidney injury
Wen, Y., Xu, L., Melchinger, I., Thiessen‐Philbrook, H., Moledina, D. G., Coca, S. G., Hsu, C., Go, A. S., Liu, K. D., Siew, E. D., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167731 · Cited by 84
Self-citationFacing the Challenge of Drug-Induced Acute Interstitial Nephritis
Sanchez-Alamo, B., Cases-Corona, C., & Fernandez-Juarez, G. (2023) · Nephron · doi:10.1159/000525561 · Cited by 71
Miao, J., Thongprayoon, C., Krisanapan, P., Buglioni, A., Craici, I. M., & Cheungpasitporn, W. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.026 · Cited by 18
Floris, M., Trevisani, F., Angioi, A., Lepori, N., Simeoni, M., Cabiddu, G., Pani, A., & Rosner, M. H. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000540908 · Cited by 17
Imaging kidney inflammation using an oxidatively activated MRI probe
Rosales, I. A., Zhou, I. Y., Ay, İ., Sojoodi, M., Sise, M. E., & Gale, E. M. (2024) · Kidney International · doi:10.1016/j.kint.2024.05.027 · Cited by 13
Metadata
- Authors
- Moledina, D. G., & Perazella, M. A.
- Affiliations
- Yale University (US)
- Veterans Health Administration (US)
- Venue
- Kidney360
- Published
- 2021-06
- Volume
- 2
- Issue
- 6
- Pages
- 1051-1055
- ISSN
- 2641-7650 (ISSN-L)
- PMC
- PMC8791367
- OpenAlex
- W3150376309
- Cited by
- 25
- References
- 27
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 1 · 2022: 3 · 2021: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Kidney360 (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Nephrology › Nephrotoxicity and Medicinal Plants
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- acute interstitial nephritis, acute kidney injury, drug-induced nephrotoxicity, immune checkpoint inhibitors, renal biopsy, diagnosis, end-stage renal disease, chronic kidney disease, interstitial fibrosis, standardization of care
- MeSH terms
- Humans, Nephritis, Interstitial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Challenges of Acute Interstitial Nephritis: Time to Standardize. https://app.cochat.ai/papers/10.34067/kid.0001742021
- The paper
- Moledina, D. G., & Perazella, M. A. (2021). The Challenges of Acute Interstitial Nephritis: Time to Standardize. Kidney360. https://doi.org/10.34067/kid.0001742021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.